老年患者降低LDL胆固醇的疗效与安全性:随机对照试验的系统综述与荟萃分析
BACKGROUND: The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients.…
要点
- LDL胆固醇每降低1 mmol/L,≥75岁患者主要血管事件风险降低26%。
- 老年患者中他汀与非他汀治疗的获益无统计学差异。
- 心血管死亡、心梗、卒中和冠脉血运重建等各组分均观察到获益。
核心结论
- 在≥75岁患者中,降脂治疗降低心血管事件的效果与75岁以下患者相当。
- 结果支持在老年患者中强化降脂治疗(包括非他汀治疗)的指南推荐。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE和Embase 2015年3月1日至2020年8月14日文献,无语言限制。
- 纳入2018年ACC/AHA指南推荐降脂药物的心血管结局随机对照试验,中位随访至少2年,含≥75岁患者数据。
临床怎么用
- 对≥75岁患者,可依据其心血管风险考虑降脂治疗,包括非他汀类药物。
- 不应仅因年龄≥75岁而排除降脂治疗;具体用药需结合个体情况。
局限性
- 研究为试验水平聚合数据的荟萃分析,非个体患者数据。
- 排除心衰和透析患者,结论不适用于该人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical benefit of LDL cholesterol lowering treatment in older patients remains debated. We aimed to summarise the evidence of LDL cholesterol lowering therapies in older patients. METHODS: In this systematic review and meta-analysis, we searched MEDLINE and Embase for articles published between March 1, 2015, and Aug 14, 2020, without any language restrictions. We included randomised controlled trials of cardiovascular outcomes of an LDL cholesterol-lowering drug recommended by the 2018 American College of Cardiology and American Heart Association guidelines, with a median follow-up of at least 2 years and data on older patients (aged ≥75 years). We excluded trials that exclusively enrolled participants with heart failure or on dialysis because guidelines do not recommend lipid-lowering therapy in such patients who do not have another indication. We extracted data for older patients using a standardised data form for aggregated study-level data. We meta-analysed the risk ratio (RR) for major vascular events (a composite of cardiovascular death, myocardial infarction or other acute coronary syndrome, stroke, or coronary revascularisation) per 1 mmol/L reduction in LDL cholesterol. FINDINGS: Data from six articles were included in the systematic review and meta-analysis, which included 24 trials from the Cholesterol Treatment Trialists' Collaboration meta-analysis plus five individual trials. Among 244 090 patients from 29 trials, 21 492 (8·8%) were aged at least 75 years, of whom 11 750 (54·7%) were from statin trials, 6209 (28·9%) from ezetimibe trials, and 3533 (16·4%) from PCSK9 inhibitor trials. Median follow-up ranged from 2·2 years to 6·0 years. LDL cholesterol lowering significantly reduced the risk of major vascular events (n=3519) in older patients by 26% per 1 mmol/L reduction in LDL cholesterol (RR 0·74 [95% CI 0·61-0·89]; p=0·0019), with no statistically significant difference with the risk reduction in patients younger than 75 years (0·85 [0·78-0·92]; pinteraction=0·37). Among older patients, RRs were not statistically different for statin (0·82 [0·73-0·91]) and non-statin treatment (0·67 [0·47-0·95]; pinteraction=0·64). The benefit of LDL cholesterol lowering in older patients was observed for each component of the composite, including cardiovascular death (0·85 [0·74-0·98]), myocardial infarction (0·80 [0·71-0·90]), stroke (0·73 [0·61-0·87]), and coronary revascularisation (0·80 [0·66-0·96]). INTERPRETATION: In patients aged 75 years and older, lipid lowering was as effective in reducing cardiovascular events as it was in patients younger than 75 years. These results should strengthen guideline recommendations for the use of lipid-lowering therapies, including non-statin treatment, in older patients. FUNDING: None.
引用
- Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020. PMID: 33186535. doi:10.1016/S0140-6736(20)32332-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。